GPC3 and hepatocellular carcinoma: This phase I trial demonstrated that GPC3-CAR T-cell is effective and safe for patients with GPC3-positive HCC and that it has robust anticancer potential when combined with lymphodepleting conditioning (NCT02395250) (104).